Pharamax

quienessomos

Our Goal:

Boost Medical Research

ABOUT Pharmax

We provide clinical trial services ranging from phase II through phase IV to branded pharmaceutical drug, generic drug and medical device companies. Our services have been contracted with by more than 20 of the leading Sponsors and CROs to participate in large-scale and fast-track studies.

 

Research and Staff Experience:

Our research staff has experience conducting clinical trials in the following therapeutic indications:

  • Alzheimer’s disease
  • Asthma
  • Atherothrombotic disease
  • Atrial fibrillation
  • Autism
  • Benign prostatic hyperplasia
  • Bipolar disorder
  • Chronic Kidney Disease
  • Colorectal cancer
  • Constipation and Chronic idiopathic constipation
  • COPD
  • Crohn's disease
  • Diabetes mellitus type I and II
  • Diverticulitis
  • Epilepsy
  • Fatty liver
  • Gastric ulcers
  • General anxiety disorder
  • GERD
  • Gout
  • Hypercholesterolemia
  • Hypertension
  • Hypoactive sexual desire disorder
  • Hypogonadism
  • Iron deficiency anemia
  • Irritable bowel syndrome (IBS)
  • Onychomycosis
  • Osteoarthritis
  • Lower Back Pain
  • Major depression disorder (MDD)
  • Migraines
  • Myocardial infarction
  • NASH
  • Nycturia
  • Parkinson disease
  • Prostatic hyperplasia
  • Psychosis
  • Rheumatoid arthritis
  • Schizophrenia
  • Smoking cessation
  • Testicular hypofunction
  • Tobacco abuse
  • Tourette syndrome
  • Ulcerative colitis (UC)
  • Urinary tract infections
  • Vaccines (Flu, Influenza, Pneumococcal, etc.)

Patient Demographics:

Our center and investigators have access to diverse patient population including healthy and treatment-naive subjects. Volunteers in our studies are largely Hispanics and Latino Americans.  The largest age group is adults between 55 and 75 years of age with 47% of total. Meanwhile, women account for 57% of our total patient population and 30% of the total patient population is reporting to be healthy.

Performance Indicators:

  • Participation in clinical trials: 241
  • Overall screening failure ratio: 43%
  • Overall post-randomization subject dropout rate: 18%
  • CTA / Budget turn-around time: 5-7 business days 
  • Regulatory submission turn-around time: 5 business days
  • EDC / IWRS capabilities: Yes
  • CRF submission turn-around time: Max. 24 hours

When partnering with us you will benefit from:

  • Good clinical practice,
  • Multiple areas of expertise,
  • Responsiveness and efficiency,
  • Combined medical and technical knowledge,
  • Adaptive data management service,
  • Patient recruitment and retention,
  • An organized trial system,
  • Access to specific patient populations,
  • Reasonable budget

For more information about partnering with us or accessing feasibility information from the site, click here. A business development representative will contact you shortly.

Thank you for your interest in Pharmax Research Clinic.